Clinical Trials Browser

Phase 1 × MEDI-570 × 90 days × Clear all

NCT02520791 2026-03-18

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Phase 1 Active not recruiting

DermatologicLymphoid

Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous